Almonertinib mesylate

Research use only, not for human use.

Almonertinib mesylate is an irreversible inhibitor of EGFR tyrosine kinase with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate can be used in the non-small cell lung cancer studies.

Almonertinib mesylate is an irreversible inhibitor of EGFR tyrosine kinase with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate can be used in the non-small cell lung cancer studies.(In Vitro):Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Additionaly, HS-10296 could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q.

HS-10296 mesylate is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC. Additionaly, HS-10296 mesylate could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q.

——

HS-10296 mesylate

Angiogenesis

EGFR

Na+ channel

——

——

2134096-06-1

621.75

C31H39N7O5S

>98% (HPLC)

In Vitro:?DMSO : 31.25 mg/mL (50.26 mM)

C=CC(NC1=CC(NC2=NC=CC(C3=CN(C4CC4)C5=C3C=CC=C5)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O

——

(-20℃)

With Ice Pack

≥ 2 years